CORE A (Administration and Informatics) The Administrative Core is responsible for program planning and evaluation, operations management, organization of meetings, financial stewardship, and informatics services. Key Core A functions are to: ?Provide scientific and administrative oversight to all components of the Consortium. ?Coordinate communication and organize meetings between CRC investigators, staff, DSMB, external and internal advisory boards, ?Execute effective planning and evaluation systems to monitor program performance and efficiency in regards to resource management. ?Monitor for compliance with NIH, NCI, FDA, DHHS, and participating organizations, and render reports concerning such monitoring. Monitor use of human subjects, animal subjects, and tissue specimens. ?Develop and maintain specific policies and procedures to ensure the quality and confidentiality of all CRC data and associated information management systems. Maintain ongoing research into the enhancement of said policies to ensure compliance with evolving regulatory and legislative requirements. ?Manage grants/contracts, perform fiscal oversight /management, and disburse funds. ?Provide information management systems, including clinical, basic science, and administrate data collection, storage, and analysis instruments. ?Expand current information management systems to incorporate new data sets and data management requirements. ?Provide the community and CLL patients specifically, with information regarding CRC research activities and general OIL educational materials.
The primary objective of Core A is to enable the efficient and effective operation and coordination of consortium-wide projects and cores. This objective is motivated by the CRCs overall mission to help develop curative strategies for patients with Chronic Lymphocytic Leukemia.
|Kashyap, Manoj K; Kumar, Deepak; Jones, Harrison et al. (2016) Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget 7:2809-22|
|Lamothe, Betty; Wierda, William G; Keating, Michael J et al. (2016) Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. Clin Cancer Res 22:4712-26|
|Oakes, Christopher C; Seifert, Marc; Assenov, Yassen et al. (2016) DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet 48:253-64|
|Balatti, Veronica; Acunzo, Mario; Pekarky, Yuri et al. (2016) Novel mechanisms of regulation of miRNAs in CLL. Trends Cancer 2:134-143|
|Lampson, Benjamin L; Kasar, Siddha N; Matos, Tiago R et al. (2016) Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128:195-203|
|Salzer, Elisabeth; Cagdas, Deniz; Hons, Miroslav et al. (2016) RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. Nat Immunol 17:1352-1360|
|Dhar, Sachin; La Clair, James J; LeÃ³n, Brian et al. (2016) A Carbohydrate-Derived Splice Modulator. J Am Chem Soc 138:5063-8|
|Hawkins, Edwin D; Duarte, Delfim; Akinduro, Olufolake et al. (2016) T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature 538:518-522|
|Sarkar, Aloke; Balakrishnan, Kumudha; Chen, Jefferson et al. (2016) Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget 7:3461-76|
|Thompson, Philip A; O'Brien, Susan M; Xiao, Lianchun et al. (2016) Î²2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia. Cancer 122:565-73|
Showing the most recent 10 out of 440 publications